T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2776
Luxfer Holdings
LXFR
$457M
| $210K | ﹤0.01% |
15,485
+1,832
| +13% | +$23.8K |
|
|
INGM
2777
Ingram Micro Holding
INGM
$6.54B
| $210K | ﹤0.01% |
+9,806
| New | +$213K |
|
|
BRCB
2778
Black Rock Coffee Bar Inc
BRCB
$181M
| $210K | ﹤0.01% |
+9,427
| New | +$219K |
|
2779
Health Catalyst
HCAT
$135M
| $209K | ﹤0.01% |
87,428
+5,100
| +6% | +$13.9K |
|
2780
Organogenesis Holdings
ORGO
$230M
| $209K | ﹤0.01% |
40,278
+3,825
| +10% | +$18.5K |
|
2781
Ardmore Shipping
ASC
$707M
| $208K | ﹤0.01% |
19,619
+482
| +3% | +$5.73K |
|
2782
3D Systems Corp
DDD
$601M
| $208K | ﹤0.01% |
116,997
| – | – |
|
2783
Resources Connection
RGP
$147M
| $207K | ﹤0.01% |
40,992
+24,580
| +150% | +$117K |
|
2784
Cricut
CRCT
$1.24B
| $206K | ﹤0.01% |
41,465
+4,785
| +13% | +$24.4K |
|
|
GPMT
2785
Granite Point Mortgage Trust
GPMT
$59.3M
| $206K | ﹤0.01% |
85,539
| – | – |
|
2786
Red River Bancshares
RRBI
$679M
| $206K | ﹤0.01% |
+2,871
| New | +$196K |
|
2787
MGP Ingredients
MGPI
$392M
| $204K | ﹤0.01% |
+8,383
| New | +$204K |
|
2788
Sanara MedTech
SMTI
$314M
| $204K | ﹤0.01% |
8,698
+2,100
| +32% | +$54.2K |
|
2789
Donegal Group Class A
DGICA
$694M
| $203K | ﹤0.01% |
+10,144
| New | +$199K |
|
2790
PubMatic
PUBM
$798M
| $203K | ﹤0.01% |
22,847
-12,465
| -35% | -$109K |
|
|
TCAL
2791
T. Rowe Price Capital Appreciation Premium Income ETF
TCAL
$296M
| $203K | ﹤0.01% |
+8,587
| New | +$207K |
|
2792
Forrester Research
FORR
$225M
| $202K | ﹤0.01% |
24,807
-16,219
| -40% | -$127K |
|
2793
Ribbon Communications
RBBN
$379M
| $202K | ﹤0.01% |
69,822
+9,103
| +15% | +$29.4K |
|
2794
America Movil
AMX
$70B
| $201K | ﹤0.01% |
9,700
| – | – |
|
2795
Eve Holding
EVEX
$979M
| $201K | ﹤0.01% |
50,158
+23,764
| +90% | +$104K |
|
|
ITIC
2796
Investors Title Co
ITIC
$531M
| $201K | ﹤0.01% |
803
+49
| +6% | +$12.9K |
|
2797
Sight Sciences
SGHT
$462M
| $201K | ﹤0.01% |
25,283
+4,498
| +22% | +$28.7K |
|
2798
FuelCell Energy
FCEL
$1.61B
| $200K | ﹤0.01% |
27,252
-5,522
| -17% | -$45.1K |
|
|
SRTA
2799
Strata Critical Medical Inc
SRTA
$531M
| $199K | ﹤0.01% |
41,282
+7,198
| +21% | +$34.8K |
|
2800
HighPeak Energy
HPK
$941M
| $199K | ﹤0.01% |
+41,863
| New | +$252K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.